雷递网 雷建平 12月17日 卓正医疗控股有限公司（简称："卓正医疗"）日前通过上市聆讯，准备在港交所上市。 卓正医疗2025年前8个月营收为6.96亿元，期内利润为8321万元。 8个月营收为6.96亿 卓正医疗于2012年在深圳创立，采用在线、线下一体化服务的新模式，在北京、上海、广州、深圳、成都、重庆、武汉、长沙、苏州、杭州等城市运营近30 家物理网点。 卓正医疗的服务涵盖内科及全科、外科、妇产科、儿科、齿科、皮肤科及医学美容、眼科、耳鼻喉科、个性化体检、日间手术、航空转运、国际转诊等多个 类别。 自2024年1月至3月，卓正医疗收购了武汉神龙天下合共51.04%股权，武汉神龙天下拥有武汉北斗星儿童医院及两家武汉诊所。武汉神龙天下已自2024年3月 28日起成为卓正医疗的非全资附属公司。 招股书显示，卓正医疗2022年、2023年、2024年营收分别为4.73亿、6.9亿、9.59亿元；毛利分别为4398万元、1.34亿元、2.26亿元；经营亏损分别为1.37亿、 6693万、4688万元；期内利润分别为-2.22亿、-3.53亿元、8023万元。 | | | 截至12月31日止年度 | | 截至8月3 ...

Core Viewpoint - Kangji Medical Holdings Limited plans to initiate a privatization delisting process with an overall valuation of approximately HKD 11.2 billion [2] Group 1: Privatization Details - The privatization is initiated by a consortium led by founder Zhong Ming, along with Shentu Yinguang, global private equity giant TPG, TPG's NewQuest V Fund, and Qatar Investment Authority's Al-Rayyan Holding [5] - The proposed share cancellation price is HKD 9.25 per share, representing a 21.7% premium over the closing price of HKD 7.6 on June 30, 2025, and exceeding the highest closing price of HKD 8.66 since 2022 [5] - Upon completion of the transaction, Kangji Medical will become a wholly-owned subsidiary of the offeror and will delist from the Hong Kong Stock Exchange [5] Group 2: Financial and Ownership Structure - The offeror consortium currently holds 74.75% of Kangji Medical's shares and has received irrevocable support commitments from some institutional shareholders [6] - After privatization, Zhong Ming and his wife will hold 40% of the ultimate holding company (TopCo) through Fortune Spring ZM and Fortune Spring YG, maintaining their position as the largest shareholders [6] - The funding for the transaction includes HKD 2.08 billion in equity financing and external debt financing, with a total cash consideration of approximately HKD 5.818 billion [6] Group 3: Company Background and Performance - Kangji Medical was established in 2004 and raised HKD 3.6 billion when it listed on the Hong Kong Stock Exchange in 2020, becoming one of the largest healthcare IPOs that year [6] - The company's products cover multiple departments, including obstetrics and gynecology and general surgery, serving over 3,500 hospitals in more than 90 countries and regions, including over 1,000 top-tier hospitals [6] - In 2024, Kangji Medical reported revenue of HKD 1.008 billion and a net profit of HKD 581 million, achieving double growth for five consecutive years, although the growth rate fell below 10% for the first time due to centralized procurement policies [6]